Core Viewpoint - The stock of Xingye Yinxin (sz000426) reached its daily limit, closing at 63.67 yuan with a 10% increase, driven by resource acquisitions, performance growth, and the restructuring of its controlling shareholder [1][2]. Group 1: Company Performance - The company completed the acquisition of 85% of Yubang Mining and 100% of Atlantic Tin Industry, enhancing its resource reserves and advancing its international resource layout, which is expected to strengthen long-term competitiveness and sustainable development [2]. - For the period from January to September 2025, the company reported revenue of 4.099 billion yuan, a year-on-year increase of 24.36%, and a net profit of 1.364 billion yuan, up 4.94%, indicating steady growth in Q3 [2]. - The net cash flow from operating activities reached 2.742 billion yuan, reflecting a significant year-on-year increase of 118.66%, showcasing the company's improved operational status [2]. Group 2: Market and Technical Analysis - The completion of the restructuring plan for Xingye Group has eliminated long-term uncertainties, contributing to the continuous improvement of the company's governance structure and stable development [2]. - On January 26, 2026, the non-ferrous metal sector saw active performance from several stocks, with Xingye Yinxin's limit-up creating a certain sectoral linkage effect [2]. - Technical indicators such as the MACD forming a golden cross and a breakout of the BOLL channel may attract more technical investors, with significant inflows of large orders indicating strong interest from major funds [2].

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company's core business shows stable growth, driven by both R&D and restructuring efforts [8] - In 2024, the company achieved total revenue of 25.435 billion yuan, a year-on-year increase of 3.71%, while the net profit attributable to shareholders was 1.330 billion yuan, a decrease of 37.70% [8] - The company is focusing on core products and accelerating R&D innovation, with over 500 projects in the pipeline, including more than 60 innovative drug projects [8] Financial Performance Summary - Total revenue forecast for 2024 is 25.435 billion yuan, with a projected growth rate of 3.71% [8] - The net profit attributable to shareholders is expected to be 1.330 billion yuan in 2024, with a significant decrease of 37.70% [8] - The earnings per share (EPS) for 2024 is projected at 0.81 yuan, with a P/E ratio of 25.56 [8] - The company’s R&D expenses for 2024 are estimated at 1.471 billion yuan, reflecting a slight increase of 0.59% [8] - The company’s core anesthetic business is expected to grow steadily, with net profit forecasts for 2025 and 2026 adjusted to 2.224 billion yuan and 2.653 billion yuan, respectively [8]